ASM Program 2021

 

Tuesday 12 October 2021 AEDT
Tues: 11.00 - 12.30 | AEDT
08.00 - 09.30 | AWST
10.00 - 11.30 | AEST
10.30 - 12.00 | ACDT
13.00 - 14.30 | NZDT

Combined Study Coordinator and Consumer Forum
Co-Chairs: Jan Mumford and Roslynn Murphy


11.00 – 11.05 Welcome and introduction

11.05 – 11.20 Health literacy of cancer patients
Presenter: Rachel Cameron

11.20 – 11.40  Adaptive Trial Design
Presenter: Kylie Shackleton

11.40 – 11.55 New Zealand – GI oncology trials (landscape/overview/treatment) 
Presenter: Sarah Benge

11.55 – 12.15 Learnings & Adaptations from COVID-19 – perspectives from Carer & Study Coordinator
Presenter: Gillian Worden
Presenter: Searalen Chinnathumby

12.15 – 12.30 Q&A

Break
Tues: 13.30 - 14.25 | AEDT
10.30 - 11.25 | AWST
12.30 - 13.25 | AEST
13.00 - 13.55 | ACDT
15.30 - 16.25 | NZDT

Study Coordinator Meeting 1
Co-Chairs: Laura Carolan and Sally Dean


13.30 – 13.35 Welcome and introduction

13.35 – 13.50 Statistics and Data Management
Presenter: Siavash Foroughi

13.50 – 14.05 Conducting Clinical Trials in New Zealand
Presenter: Sarah Benge

14.05 – 14.25 Implementing Teletrials
Presenter: Narelle McPhee

Break
Tues 14.30 - 15.15 | AEDT
11.30 - 12.15 | AWST
13.30 - 14.15 | AEST
14.00 - 14.45 | ACDT
16.30 - 17.15 | NZDT

Study Coordinator Meeting 2
Co-Chair: Roslynn Murphy and Evonne Tim


14.30 – 14.45 Early versus Phase Trials
Presenter: James Lynam

14.45 – 15.00 Project management in clinical trials: COVID-19
Presenter: Kylie Shackleton

15.00-15.15 Q&A 

 

Wednesday 13 October 2021 AEDT
Wed: 08.45- 09.35 | AEDT
05.45 - 06.35 | AWST
07.45 - 08.35 | AEST
08.15 - 09.05 | ACDT
10.45 - 11.35 | NZDT

Opening Plenary

 

Back to the Future: using the retrospectoscope

How did we get to where we are now?  Communication, collaboration, inclusivity and multidisciplinary – the strengths of AGITG over 30 years.

Panel discussion with AGITG pioneers: Haryana Dhillon, Trevor Leong, Eva Segelov, John Simes, Mark Smithers, and John Zalcberg

Break
Wed: 09.50 - 11.50 | AEDT
06.50 - 08.50 | AWST
08.50 - 10.50 | AEST
09.20 - 11.20 | ACDT
11.50 - 13.50 | NZDT

AGITG Early Colorectal Cancer Trials
Co-Chairs: Niall Tebbutt and Shehara Mendis


Presentations by trial investigators for:

  • SPAR – Michael Jameson
  • DYNAMIC-III & DYNAMIC-Rectal – Jeanne Tie
  • ASCOLT – Mark Jeffrey
  • RENO – Chris Karapetis
  • OXTOX – Janette Vardy
  • FORECAST-1 – Andrew Stevenson
  • LICPIC – Stephen Smith

Followed by:

AGITG Early Colorectal Cancer Trials Portfolio – How does this fit in to the International Context?

Presenter: Tim Price

Followed by Q&A

Break
Wed: 12.20 - 14.20 | AEDT
09.20 - 11.20 | AWST
11.20 - 13.20 | AEST
11.50 - 13.50 | ACDT
14.20 - 16.20 | NZDT

AGITG Advanced Colorectal Cancer Trials
Co-Chairs: Chris Karapetis and Margaret Lee


Presentations by trial investigators for:

  • ALT-TRACC – Vanessa Wong
  • MONARCC – Matthew Burge
  • RoLaCaRT-1 – Grace Gard
  • LIBERATE – Daniel Cox
  • MODULATE – Niall Tebbutt
  • VADER – Fiona Chionh
  • RESOLUTE – Jeanne Tie
  • GENESCREEN-5FU – Stephen Ackland

Followed by:

AGITG Advanced Colorectal Cancer Trials Portfolio – How does this fit in to the International Context?

Presenter: Sue Anne McLachlan

Followed by Q&A

Break
Wed: 14.50-15.20 | AEDT
11.50 - 12.20 | AWST
13.50 - 14.20 | AEST
14.20 - 14.50 | ACDT
16.50 - 17.20 | NZDT

Breakout Discussion Groups

Wed: 15.30 - 16.15 | AEDT
12.30 - 13.15 | AWST
14.30 - 15.15 | AEST
15.00 - 15.45 | ACDT
17.30 - 18.15 | NZDT

Keynote Session – Sponsored by Bristol Myers Squibb
Co-Chairs: John Zalcberg and Stephanie Lim


Evolution and revolution of clinical trials in GI cancer: endpoints and magnitude of clinical benefits 

The gold standard for establishing the efficacy of new cancer therapies is a phase III randomized controlled trial. Over the past 3 decades, there has been a marked shift in the primary endpoint of cancer clinical trials with increasing use of surrogate endpoints, as well as an increase in trial sample size. Several reports have shown that the incremental gain of new cancer therapies is getting smaller over time. The expanding number of systemic therapy options has raised important considerations regarding patient-reported toxicity and financial toxicity. It is therefore imperative that regulatory bodies carefully consider which treatments will offer the largest clinical benefit within a sustainable health care system. To this end, both ESMO and ASCO has established task forces to rank the magnitude of benefit of the new anti-cancer agents.

Presenter: Alberto Sobrero

Wed: 15.30 - 17.00 | AEDT
12.30 - 14.00 | AWST
14.30 - 16.00 | AEST
15.00 - 16.30 | ACDT
17.30 - 19.00 | NZDT

Radiation Oncology Workshop Oesophageal Cancer
Co-Chairs: Meredith Johnston and Dominique Lee


Gullets and Mullets: What’s changed in 30 years of oesophageal cancer treatment (and hairstyles)?

It has been almost thirty years since the RTOG 85-01 trial established definitive CRT as the standard management for non-operative localised oesophageal cancer. During this time, patient demographics and tumour subtype distribution have changed, additionally radiation techniques an organ support during chemotherapy have improved dramatically. Despite a lack of randomised data directing radiation oncologists, greater interest in elective nodal irradiation, dose escalation, organ preservation, altered concurrent chemotherapy regimes and immunotherapy have laid the foundations for oesophageal and GOJ cancers to be increasingly complex. In this interactive radiation workshop, we discuss these controversies through case presentations.

Case Studies

Panel discussion: Karin Haustermans and Trevor Leong

Thursday 14 October 2021 AEDT
Thurs: 07.45 - 09.00 | AEDT
04.45 - 06.00 | AWST
06.45 - 08.00 | AEST
07.15 - 08.30 | ACDT
09.45 - 11.00 | NZDT

Keynote Session: Practical Genomics in GI Cancer – Sponsored by Servier 
Co-Chairs: Stephen Ackland and Oliver Sieber


Geoff Cooper first imagined Ras mutations as a driver of cancer at the cusp of the 1980s. “A Genetic model of colorectal carcinogenesis” by Fearon and Vogelstein published in 1988 had a huge impact as measured by ~14,000 citations; expanding our attention to three genes. DPD deficiency causing 5FU toxicity was first reported in 1985. These landmark reports are 4 decades ago and perhaps now is a good moment to reflect on how to exploit the massive amount of subsequent genomics knowledge into practice.

Screening for DPD deficiency: Should it be done before starting fluoropyrimidine?

Presenter:  Julien Taieb

Genomic sequencing in GI Cancer: What you need to know in the clinic

Presenter: Kortnye Smith

Followed by Q&A

Break
Thurs: 09.15 - 10.45 | AEDT
06.15 - 07.45 | AWST
08.15 - 09.45 | AEST
08.45 - 10.15 | ACDT
11.15 - 12.45 | NZDT

New Concepts Symposium –  Sponsored by Amgen
Co-Chairs: Lorraine Chantrill and Katrin Sjoquist


The New Concepts Symposium is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international guests in terms of perspective, international interest and relevance. A good idea can be tested and a perception gained on whether to take the concept forward to a more formal review by the Upper or Lower GI Working Party. The identification of other AGITG members who may wish to assist in progressing the concept as an AGITG supported protocol is also possible. The winner of the Best New Concept Award, sponsored by Amgen, will receive a $3,500 prize and a framed certificate. The runner up will receive a $1,500 prize and framed certificate. The Awards are presented at the Annual Scientific Meeting Awards Session taking place on Friday 15 October, and details of the Award recipients are published on the AGITG website and in the Annual Report.

1 . A phase 1 study of a novel drug-eluting polymer implant for intra-tumoural delivery of 5FU, Folinic Acid, Irinotecan and Oxaliplatin (FOLFIRINOX) in combination with systemic chemotherapy for inoperable locally advanced pancreatic cancer (ILAPC).
Presenter: Morteza Aghmesheh
Faculty reviewer: Yu Jo Chua

2.BIOMARCER1 (Biomarker informed optimal management of advanced ras wild type colorectal cancer)
Presenter: Shehara Mendis
Faculty reviewer: Sina Vatandoust

3.Amivantamab activity in Colorectal carcinoma previously treated with an EGFR monoclonal antibody – The ACE study
Presenter: Tim Clay
Faculty reviewer: Connie Diakos

Break
Thurs: 11.15 - 12.15 | AEDT
08.15 - 09.15 | AWST
10.15 - 11.15 | AEST
10.45 - 11.45 | ACDT
13.15 - 14.15 | NZDT

Best of the Best – Sponsored by Servier 
Co-Chairs: Stephen Ackland and Oliver Piercey


The AGITG Annual Scientific Meeting accepts abstracts for posters for selection by the Executive Organising Committee.  Posters are displayed in the exhibition area. Four posters are chosen for presentation in the Best of the Best Session. Each presenter has seven minutes to present with three minutes for questions. Four posters are also chosen for Fast Forward presentation.

The AGITG recognises excellence in the Posters Sessions at each annual meeting. The winning presenter in the Posters Session receives a $3,500 prize and framed certificate. The winning presenter in the Fast Forward session receives $1,500 and a framed certificate. The Awards, sponsored by Servier are presented at the Annual Scientific Meeting Awards on Friday 15 October, and details of the Award recipients are published on the AGITG website and in the Annual Report.

Long term survival and toxicity in patients with progressive advanced neuroendocrine tumours treated with Lutetium-177-Octreotate Peptide Receptor Radionuclide Therapy: A Western Australian long term follow-up study
Kim Kennedy

Real-world characteristics and outcomes of potentially resectable oligometastatic colorectal cancer
Andrew Parsonson

Health economic evidence for circulating tumour DNA guided adjuvant chemotherapy in stage II colorectal cancer
Yat Hang To

Comprehensive genomic profiling reveals novel opportunities for treatment-refractory gastrointestinal cancers
Wei Yen Chan

Break
Thurs: 12.45 - 14.40 | AEDT
09.45 - 11.40 | AWST
11.45 - 13.40 | AEST
12.15 - 14.10 | ACDT
14.45 - 16.40 | NZDT

Translational Science Symposium – Sponsored by MSD
Co-Chairs: Vicki Whitehall and John Mariadason


The Ins and Outs of GI tumours

Seven experts each present for 15 minutes on a topic of their choice, followed by a 10 minute panel discussion

Technological underpinning of the FORECAST-1 Trial study
Presenter: Oliver Sieber

Early onset colorectal cancer
Presenter: Dan Buchanan

New Treatments for Bowel Cancer-ideas from the lab
Presenter: Susan Woods

Metabolic Reprogramming in Pancreatic Tumours
Presenter: Phoebe Phillips

Immunosuppression and therapy response in hepatocellular carcinoma
Presenter: Ankur Sharma

STAT pathway activation in CR
Presenter: Jennifer Huynh

Dual targeting HDACs and the EGFR/MAPK pathway in mCRC from idea to trial
Presenter: Laura Jenkins

Followed by a panel discussion

Break
Thurs: 15.10 - 16.55 | AEDT
12.10 - 13.55 | AWST
14.10 - 15.55 | AEST
14.40 - 16.25 | ACDT
17.10 - 18.55 | NZDT

Translational Science Symposium – Sponsored by Bayer
Co-Chairs: Robert Ramsay and Laura Jenkins


Determinants of patient outcome, therapy response and new targets

It is proving unhelpful to consider colorectal tumours as a single entity. This is clearly demonstrated by genomic analyses into definable consensus molecular signatures that underpin marked differences in responses to standard of care therapies. Beyond these signatures the deep delving into the genetic drivers of CRC has been de rigueur and some are now showing exquisite and surprising responses to targeted agents. All that said it is truly remarkable how the immune milieu so impressively governs patient outcomes. Putting all this together, it is highly likely that advances for our patients will depend heavily on embracing these exciting developments as best practise.

Where to next with stratifying CRC by consensus molecular signatures?
Presenter: Jonathan Loree

At last there are agents to target the RAS/RAF pathway with precision
Presenter: Jayesh Desai

The tumour immune microenvironment over-arching our understanding of CRC – the development and implementation of the “Immunoscore” platform
Presenter: Jerome Galon

Friday 15 October 2021 AEDT
Fri: 07.45 - 09.35 | AEDT
04.45 - 06.35 | AWST
06.45 - 08.35 | AEST
07.15 - 09.05 | ACDT
09.45 - 11.35 | NZDT

Keynote Session: HCC

Current and Emerging Multimodality Treatment Options for Hepatocellular Carcinoma
Co-Chairs: Chris Nahm, Sumitra Ananda and Dominique Lee


The management of patients with hepatocellular carcinoma (HCC) is complex where treatment options are determined both by disease extent and the severity of underlying liver disease. Additionally, no single staging system is applicable to all patients and a wide variety of treatments are offered by different specialties: surgery, radiation oncology, medical oncology, hepatology and interventional radiology. New treatments and indications are also evolving rapidly, challenging attempts to generate algorithmic approaches to the treatment of HCC. It is therefore critical that individual patients undergo multidisciplinary evaluation and planning to generate an optimal management plan.

Treatment sequencing in patients with advanced HCC: Is there an optimal strategy?
Presenter: Ghassan Abou-Alfa

Emerging and novel therapeutic approaches in advanced HCC
Presenter Simone Strasser

The role of SBRT in HCC
Dominique Lee

Management of early HCC multi-focal HCC
Pierce Chow

Panel discussion:
Chris Nahm, Sumitra Ananda, Dominique Lee, Simone Strasser and Pierce Chow

Break
Fri: 10.05 - 10.45 | AEDT
07.05 - 07.45 | AWST
09.05 - 09.45 | AEST
09.35 - 10.15 | ACDT
12.05 - 12.45 | NZDT

AGITG Awards
Chair: Lorraine Chantrill

  • AGITG Outstanding Site Award
  • Christine Aiken Memorial Award for Excellence in AGITG Study Coordination
  • AGITG Member Fundraiser of the Year Award
  • Best of New Concepts Award – Sponsored by Amgen
  • Best of Posters Award – Sponsored by Servier
  • John Zalcberg OAM Award for Excellence in AGITG Research
  • Gastric Cancer Research Grant
  • Innovation Grant
Fri: 10.45 - 11.25 | AEDT
07.55 - 08.25 | AWST
09.55 - 10.25 | AEST
10.25 - 10.55 | ACDT
12.55 - 13.25 | NZDT

Breakout Discussion Groups

Break
Fri: 11.55 - 13.15 | AEDT
08.55 - 10.10 | AWST
10.55 - 12.10 | AEST
11.25 - 12.40 | ACDT
13.55 - 15.10 | NZDT

AGITG Upper GI Cancer Research
Co-Chairs: Andrew Barbour & Bryan Chan


Presentations by trial investigators for:

  • NEO-IMPACT – Lorraine Chantrill
  • ASCEND – Andrew Dean
  • DYNAMIC-Pancreas – Belinda Lee
  • MASTERPLAN & sub-studies – Andrew Oar
  • ALT – GIST – Desmond yip
  • SSGXXII – John Zalcberg

Followed by Q&A

Break
Fri: 13.40 - 15.20 | AEDT
10.40 - 12.20 | AWST
12.40 - 14.20 | AEST
13.10 - 14.50 | ACDT
15.40 - 17.20 | NZDT

AGITG Upper GI Cancer Research (continued)
Co-Chairs: Lara Lipton & Mandi Maundura


Presentations by trial investigators for:

  • TOPGEAR – Trevor Leong
  • PALEO – Fiona Day
  • NEO-CREATE – Amitesh Roy
  • INTEGRATE IIa/b – Nick Pavlakis
  • CONTROL NETS & TR sub study – Nick Pavlakis
  • NABNEC – Lorraine Chantrill

Followed by:

AGITG Upper GI Cancer Research Portfolio – How does this fit in to the International Context?
Presenter: David Ransom

Followed by Q&A

Fri: 15.20 - 16.30 | AEDT
12.20 - 13.30 | AWST
14.20 - 15.30 | AEST
14.50 - 16.00 | ACDT
17.20 - 18.30 | NZDT

Closing Plenary – Sponsored by AstraZeneca 


AGITG into the Future: Strategy, Culture and Trial Design

For 30 years, the AGITG has been the premier cooperative GI trials group in the region, but the COVID-19 pandemic has shown that no one is immune from the need to adapt. Many current and future issues could affect the group’s survival and sustainability. Led by a panel of next-generation leaders, this session invites all members to ponder and discuss the future of the AGITG: What trial designs will we undertake in the next 5-10 years? How can we position ourselves to deliver them in the best possible way? How do we engage new talent to join the Group?

ACTA’s perspective on cooperative trials groups in the future

Presenter: John Zalcberg OAM

UK Trials and Tribulations: Perspectives from the overseas AGITG fellow

Presenter: David Lau

Panel Discussion: Belinda Lee, Jan Mumford, Ros Murphy, Sweet Ping Ng, Oliver Piercey, Belinda Steer and Deborah Wright

Close of ASM | 16.30